Jan. 7 at 3:31 PM
Mizuho reiterated
$EYPT at Top Pick, Outperform and a
$33 PT.
$OCUL $FDMT REGN
$SRZN $KOD
Here's what Mizuho said in its note to investors:
This morning, EYPT provided a corporate update outlining key milestones anticipated for 2026.
Importantly, the company remains on track to report top-line P3 data in mid-2026 for lead asset Duravyu, a novel (and potentially disruptive) extended-duration treatment in the setting of wet AMD/wAMD.
Additionally, EYPT also remains on track in dose the first patient in its P3 program for Duravyu in diabetic macular edema/DME in 1Q26.
With the company also announcing today it has ~
$300MN in cash and investments (unaudited) at YE25—with a solid cash runway into 4Q27—we find EYPT well-positioned to deliver on its key milestones in wAMD and DME in what we view to be a transformative year for the company. As such, we again highlight EYPT as a top pick for 2026.
